avdoralimab

Also Known As:

IPH 5401; IPH-5401; IPH5401

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Pneumonia (Pneumonitis) 12/01/2022 - "In this randomized trial in hospitalized patients with severe COVID-19 pneumonia, avdoralimab did not significantly improve clinical status at days 14 and 28 (funded by Innate Pharma, ClinicalTrials.gov number, NCT04371367)."
2.	COVID-19 12/01/2022 - "We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. " 12/01/2022 - "Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])." 12/01/2022 - "In this randomized trial in hospitalized patients with severe COVID-19 pneumonia, avdoralimab did not significantly improve clinical status at days 14 and 28 (funded by Innate Pharma, ClinicalTrials.gov number, NCT04371367)."